BioInfra Co., Ltd. (KOSDAQ:199730)

South Korea flag South Korea · Delayed Price · Currency is KRW
3,960.00
-10.00 (-0.25%)
At close: Apr 2, 2026
Market Cap19.14B -25.8%
Revenue (ttm)23.15B -2.9%
Net Income-9.13B
EPS-1,877.00
Shares Out4.86M
PE Ration/a
Forward PEn/a
Dividend300.00 (7.41%)
Ex-Dividend DateDec 29, 2025
Volume3,672
Average Volume11,551
Open3,940.00
Previous Close3,970.00
Day's Range3,885.00 - 3,980.00
52-Week Range3,200.00 - 7,040.00
Beta0.55
RSI46.96
Earnings Daten/a

About BioInfra

BioInfra Co., Ltd. operates as a contract research organization for phase 1 clinical trials. The company provides clinical, which undertakes clinical trials for new drug development approval (Phase I-III) and late clinical trials; immunoassay, which performs pharmacokinetic, toxicokinetic, and biomarker analysis of polymer biopharmaceuticals; and testing and inspection, which provides finished drug product quality inspection, comparative dissolution testing, and long-term stability testing. It also specializes in bioequivalence testing of gener... [Read more]

Industry Commercial Physical and Biological Research
Founded 2007
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 199730
Full Company Profile

Financial Performance

In 2025, BioInfra's revenue was 23.15 billion, a decrease of -2.87% compared to the previous year's 23.83 billion. Losses were -9.13 billion, 129.7% more than in 2024.

Financial Statements